Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Fiche publication
Date publication
septembre 2018
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre
Tous les auteurs :
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA,
Lien Pubmed
Résumé
Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Lenalidomide, Lymphoma, Follicular, drug therapy, Male, Middle Aged, Neutropenia, chemically induced, Rituximab, administration & dosage, Skin Diseases, chemically induced, Survival Rate, Thalidomide, administration & dosage
Référence
N. Engl. J. Med.. 2018 09 6;379(10):934-947